We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Refeyn Logo

Refeyn

Refeyn pioneers analytical instruments that put molecular mass measurement capabilities within easy reach for scientists. Refeyn’s unique products measure the mass of individual proteins, nucleic acids, complexes and viruses directly in solution – providing vital insights for scientific discovery, research and development and therapeutics production.

Latest Content

Cover of a Refeyn technical note on antibody aggregation analysis using mass photometry as a column-free method orthogonal to SEC-UV, featuring blue antibody structures on a dark background
App Note / Case Study

Mass Photometry, a Column-Free Orthogonal to SEC-UV

In this technical note, we explore datasets captured through mass photometry and size exclusion chromatography (SEC), comparing how they characterize the aggregation levels in different biosimilar antibodies
Banner for the 8th Annual Bioprocessing Summit Europe, March 18–20, 2025, in Barcelona, Spain and virtual (CET)
Video

Derisk Early and Accelerate Antibody Development With Mass Photometry

Stephen Maughan uses real-world data and case studies to demonstrate how mass photometry streamlines development projects involving mAbs, BsAbs, and ADCs – and how it compares to SEC
Refeyn’s SamuxMP mass photometer for AAV analytics – used for characterizing the US Pharmacopeia’s new adeno-associated virus (AAV) reference standards.
Product News

Mass Photometry Recognized by US Pharmacopeia in New AAV Reference Standards for Gene Therapy Quality

Refeyn has announced that mass photometry has been recognized by the US Pharmacopeia (USP) as a key orthogonal method for characterizing USP’s new AAV reference standards.
Scientist in lab coat working next to a REFEYN TwoMP Auto instrument in a modern laboratory setting
Product
Advertisement

TwoMP Auto - Accelerate Lead Discovery and Development with Automated Mass Photometry

Accelerate lead discovery with automated mass photometry—unlocking new possibilities in bioanalytics. Analyze up to 24 samples in just 90 minutes for efficient operator time, high precision, and minimal sample use
The gloved hands of a scientist holding badges displaying various LGBTQIA+ pride flags.
Listicle

Creating Space in Science: LGBTQIA+ Voices on Belonging in Pharma

In this listicle, LGBTQIA+ scientists offer insights into how inclusion can be built into everyday lab culture, from normalizing pronoun sharing and celebrating diverse holidays to rethinking policy and representation.
Refeyn’s TwoMP mass photometer and MassFluidix HC system newly installed at the University of Copenhagen in action with Dr. Anni Kumari.
Product News

Major Mass Photometry Milestone Achieved by Refeyn With 500th Installation Globally

Refeyn’s mass photometry tech reaches 500 installs, advancing protein research in disease and drug development globally.
A screenshot from the software.
Product News

Refeyn Launches Software Platform To Automate Mass Photometry Analysis Workflows

Refeyn, has developed and launched a custom software platform providing automated analysis of large mass photometry data sets.
Two researchers in a lab.
Product News

Refeyn Introduces New Mass Photometry Products To Streamline Biomolecular Analysis Workflows

Upgraded MassFluidix HC system launched in response to customer feedback, optimizing efficiency and quality of mass photometry experiments.
Sample loading on a Refeyn Mass Photometer.
Product News

Refeyn Establishes New Mass Photometry Scientific Advisory Board To Maximize Potential of Transformative Technology

Refeyn, announces that it has established a new Scientific Advisory Board, chaired by Justin Benesch, Professor of Biophysical Chemistry, Oxford University and co-founder of Refeyn.
A double-stranded DNA helix composed of small blue circles.
Webinar

Enhancing the Development of AAV-Based Therapeutics With Mass Photometry

On-Demand
A major challenge when developing AAV-based therapeutics is ensuring that empty AAVs that lack therapeutic DNA are removed, increasing the efficacy of the product.
Advertisement